Laureate Pharma Announces Collaboration with Boehringer Ingelheim
12 February 2007
Princeton, NJ – Laureate Pharma, Inc. is pleased to announce a preferred partnership agreement with Boehringer Ingelheim, one of the leading companies in biopharmaceutical development and manufacturing. With this collaboration, Laureate's clients will gain access to Boehringer Ingelheim's comprehensive manufacturing technology platform for biopharmaceutical products produced by mammalian cell culture.
Through this collaboration, Laureate will now offer its clients bioprocessing services that include creation and development of production cell lines using Boehringer Ingelheim's highly efficient BI HEX expression system; full-service process development and manufacture of early stage clinical supplies at Laureate's cGMP manufacturing facility in Princeton, NJ; and access to large-scale commercial production by Boehringer Ingelheim at its facility in Biberach, Germany. Laureate and Boehringer Ingelheim will harmonize bioprocessing methods to ensure seamless transfer of manufacturing activities from Laureate to Boehringer Ingelheim.
"We are delighted to announce our preferred partnership with Boehringer Ingelheim and view it as a great way to provide our clients with a complete path from clinical-scale production at Laureate to large-scale commercial manufacturing at Boehringer Ingelheim," said Robert J. Broeze, Ph.D., President and Chief Executive Officer of Laureate Pharma. "Working together, Laureate Pharma and Boehringer Ingelheim offer a comprehensive menu of manufacturing solutions in the United States and Europe."
The collaboration with Boehringer Ingelheim complements Laureate's current service offerings with high expression cell line development along with large-scale manufacturing capabilities allowing speed and flexibility, and securing high value for the customer.
"With Laureate Pharma, Boehringer Ingelheim complements its worldwide strategic manufacturing network with a strong partner for process development and clinical material supply. Our process know-how allows state of the art and time to clinic development at Laureate as well as smooth technology transfer to Boehringer Ingelheim's commercial manufacturing," commented Prof. Dr. Dr. h.c. Rolf G. Werner, Senior Vice President, Corporate Division Biopharmaceuticals.
